Macrogenics Inc (NAS:MGNX)
$ 2.97 -0.09 (-2.94%) Market Cap: 186.28 Mil Enterprise Value: 85.00 Mil PE Ratio: 0 PB Ratio: 3.23 GF Score: 50/100

MacroGenics Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 10, 2020 / 02:45PM GMT
Release Date Price: $26.96 (-0.33%)
Yigal Dov Nochomovitz
Citigroup Inc. Exchange Research - Research Analyst

Okay. Great. I think we've got everyone logged in properly. So welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi. We're starting the Novel Antibodies in Protein Therapeutics in Oncology Discussion.

Remember, if you do -- if any of the listeners have questions, you can just e-mail me at [email protected], (Operator Instructions).

So with that, it's my great pleasure to have with me 5 distinguished guests Jerry McMahon, President and CEO of Harpoon; Yannis Morel from Innate Pharma, the Head of Portfolio Strategy; Scott Koenig, President and CEO of MacroGenics; Bill Lundberg, CEO of Merus; and Ali Tehrani, President and CEO of Zymeworks.

So welcome all of you. Thank you very much for taking the time to spend with us today.

Questions & Answers

Yigal Dov Nochomovitz
Citigroup Inc. Exchange Research - Research Analyst

Maybe just to kick things off. For those that are less familiar with -- the listeners that are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot